Table 2.
Top 15 canonical pathways of differentially expressed genes between secondary follicles with Figla suppression and control.
| Ingenuity canonical pathways | p value | Ratioa | z-scoreb | Genesc |
|---|---|---|---|---|
| Molecular mechanisms of cancer | 1.32E−09 | 0.11 | N/A | Abl1, Adcy6, Apc, Aph1c, Arhgef11, Arhgef18, Atm, Atr, Birc3, Brca1, Cbl, Ccne2, Cdc25b, Cdk12, Cdk5, Cdkn2b, Crebbp, Ctnnd1, Ep300, Fzd5, Fzd7, Lrp1, Lrp5, Lrp6, Mapk11, Pak2, Pik3c2a, Prkd3, Prkdc, Ptch1, Raf1, Rhobtb1, Rhoh, Rras2, Smad3, Smad5, Sos1, Tcf4, Tgfb2, Wnt7a, Wnt8a, Xiap, Zbtb17 |
| Actin cytoskeleton signaling | 1.78E−05 | 0.106 | − 1.414 | Actr2, Apc, Arhgap24, Bcar1, Diaph3, Fgf8, Flna, Iqgap3, Mprip, Myh11, Myh9, Pak2, Pdgfb, Pik3c2a, Raf1, Rras2, Sos1, Ssh2, Tln1, Tln2, Trio, Ttn, Vav2 |
| Estrogen receptor signaling | 4.47E−05 | 0.0884 | − 3.528 | Adcy6, Cacna1d, Crebbp, Eif2b4, Ep300, Igf1r, Igf2r, Lepr, Med12, Med12l, Med13, Med13l, Med14, Mprip, Mtor, Ncoa1, Ncoa2, Ncoa3, Ncor2, Nr3c1, Pelp1, Pik3c2a, Prkd3, Prkdc, Raf1, Rras2, Sos1, Tbl1xr1, Thrap3 |
| Mouse embryonic stem cell pluripotency | 5.13E−05 | 0.136 | − 1.387 | Apc, Crebbp, Fzd5, Fzd7, Id2, Il6st, Mapk11, Pik3c2a, Raf1, Rras2, Smad5, Sos1, Tcf4, Xiap |
| Wnt/β-catenin signaling | 5.37E−05 | 0.11 | − 2.357 | Apc, Appl1, Bcl9, Crebbp, Csnk2a1, Ep300, Fzd5, Fzd7, Kremen1, Lrp1, Lrp5, Lrp6, Nr5a2, Ppp2r1b, Sox15, Tcf4, Tgfb2, Wnt7a, Wnt8a |
| Cell cycle: G2/M DNA damage checkpoint regulation | 0.000107 | 0.184 | − 0.707 | Abl1, Atm, Atr, Brca1, Cdc25b, Ep300, Plk1, Prkdc, Trip12 |
| NER Pathway | 0.0002 | 0.126 | − 1.732 | Cops4, Cops8, Ddb1, Ep300, Ercc4, Gps1, Lig3, Pole, Polr2a, Polr2d, Rfc4, Rnf111, Rpa1 |
| Glioblastoma multiforme signaling | 0.000282 | 0.103 | 1 | Apc, Fzd5, Fzd7, Igf1r, Itpr1, Mtor, Pdgfb, Pik3c2a, Raf1, Rhobtb1, Rhoh, Rras2, Sos1, Tsc1, Tsc2, Wnt7a, Wnt8a |
| Role of CHK proteins in cell cycle checkpoint control | 0.000355 | 0.158 | − 0.816 | Atm, Atr, Brca1, Mdc1, Plk1, Ppp2r1b, Rfc4, Rpa1, Tlk1 |
| Integrin signaling | 0.000794 | 0.0892 | − 1.213 | Abl1, Actr2, Arf1, Arf3, Bcar1, Itgav, Mprip, Pak2, Pdgfb, Pik3c2a, Pikfyve, Raf1, Rhobtb1, Rhoh, Rras2, Sos1, Tln1, Tln2, Ttn |
| VDR/RXR activation | 0.000933 | 0.128 | 1.414 | Csnk2a1, Ep300, Lrp5, Ncoa1, Ncoa2, Ncoa3, Ncor2, Prkd3, Rxra, Tgfb2 |
| RhoA signaling | 0.00112 | 0.106 | − 2.309 | Abl2, Actr2, Arhgef11, Cit, Igf1r, Mprip, Pi4ka, Pikfyve, Pip4k2c, Rapgef2, Rapgef6, Septin12, Ttn |
| Glioma signaling | 0.00129 | 0.109 | − 1.265 | Abl1, Camk1d, Cdkn2b, Igf1r, Igf2r, Mtor, Pdgfb, Pik3c2a, Prkd3, Raf1, Rras2, Sos1 |
| TGF-β signaling | 0.00138 | 0.115 | − 0.333 | Crebbp, Ep300, Mapk11, Raf1, Rnf111, Rras2, Smad3, Smad5, Sos1, Tgfb2, Tgif1 |
| ATM signaling | 0.00148 | 0.113 | − 1.265 | Abl1, Atm, Atr, Brca1, Crebbp, Herc2, Mapk11, Mdc1, Ppp2r1b, Tlk1 |
aRatio of listed genes found in each pathway over the total number of genes in that pathway.
bz-score positive when pathways are down-regulated in the Figla siRNA-injected group (= pathways are expected to be up-regulated by Figla), while negative when pathways are up-regulated in the Figla siRNA-injected group (= pathways are expected to be down-regulated by Figla).
cGenes in bold are down-regulated in the Figla siRNA-injected group (= genes expected to be up-regulated by Figla), while genes in normal font are up-regulated in the Figla siRNA-injected group (= genes expected to be down-regulated by Figla).